Cargando…

Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting

SIMPLE SUMMARY: Concurrent platinbased chemoradiotherapy followed by maintenance treatment with the PD-L1 inhibitor durvalumab is the new standard of care for inoperable stage III NSCLC. The present study compares the oncological outcome of patients treated with chemoradiotherapy to those treated wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taugner, Julian, Käsmann, Lukas, Eze, Chukwuka, Tufman, Amanda, Reinmuth, Niels, Duell, Thomas, Belka, Claus, Manapov, Farkhad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037429/ https://www.ncbi.nlm.nih.gov/pubmed/33807324 http://dx.doi.org/10.3390/cancers13071613

Ejemplares similares

Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients
por: Taugner, Julian, et al.
Publicado: (2021)

Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)—a German radiation oncology survey
por: Käsmann, Lukas, et al.
Publicado: (2020)

Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis
por: Flörsch, Benedikt, et al.
Publicado: (2022)

Association of Planning Target Volume with Patient Outcome in Inoperable Stage III NSCLC Treated with Chemoradiotherapy: A Comprehensive Single-Center Analysis
por: Karin, Monika, et al.
Publicado: (2020)

Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition
por: Unterrainer, Marcus, et al.
Publicado: (2021)

Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition
por: Taugner, Julian, et al.
Publicado: (2021)

Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study
por: Käsmann, Lukas, et al.
Publicado: (2023)

Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer
por: Taugner, Julian, et al.
Publicado: (2020)

Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab
por: Guggenberger, J., et al.
Publicado: (2022)

Metabolic patterns on [(18)F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment
por: Holzgreve, Adrien, et al.
Publicado: (2023)

Maximum standardized uptake value of primary tumor (SUVmax_PT) and horizontal range between two most distant PET-positive lymph nodes predict patient outcome in inoperable stage III NSCLC patients after chemoradiotherapy
por: Roengvoraphoj, Olarn, et al.
Publicado: (2020)

Clinical Management and Outcome of Grade III Pneumonitis after Chemoradioimmunotherapy for Inoperable Stage III Non-Small Cell Lung Cancer—A Prospective Longitudinal Assessment
por: Kauffmann-Guerrero, Diego, et al.
Publicado: (2021)

Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a prospective longitudinal biomarker study
por: Käsmann, Lukas, et al.
Publicado: (2022)

Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy
por: Gennen, Kathrin, et al.
Publicado: (2020)

PD-L1 expression on tumor cells as a potential predictive biomarker for patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
por: Käsmann, Lukas, et al.
Publicado: (2023)

Radiation-Induced Lung Injury: Prevention, Diagnostics and Therapy in the Era of the COVID-19 Pandemic
por: Käsmann, Lukas, et al.
Publicado: (2022)

Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy
por: Käsmann, Lukas, et al.
Publicado: (2020)

In regards to Chu et al.: Patterns of brain metastasis immediately before prophylactic cranial irradiation (PCI): implications for PCI optimization in limited-stage small cell lung cancer
por: Käsmann, Lukas, et al.
Publicado: (2020)

Initial report on feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation in node-positive non-small cell lung Cancer patients with poor prognostic factors and strongly diminished lung function: a retrospective analysis
por: Eze, Chukwuka, et al.
Publicado: (2019)

Timing of tumor-induced atelectasis resolution and pulmonary function restoration in the course of image-guided moderate hypofractionated thoracic irradiation: a case report and mini-review of literature
por: Bodensohn, Raphael, et al.
Publicado: (2021)

Investigating a Correlation between Chemoradiotherapy Schedule Parameters and Overall Survival in a real-life LD SCLC Patient Cohort
por: Manapov, Farkhad, et al.
Publicado: (2016)

PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC—current state and future directions
por: Eze, Chukwuka, et al.
Publicado: (2021)

Prophylactic cranial irradiation in small-cell lung cancer: update on patient selection, efficacy and outcomes
por: Manapov, Farkhad, et al.
Publicado: (2018)

Chemo-/immuno-/radiotherapy combination in treatment of solid cancer
por: Käsmann, Lukas, et al.
Publicado: (2019)

Evaluation of the role of remission status in a heterogeneous limited disease small-cell lung cancer patient cohort treated with definitive chemoradiotherapy
por: Manapov, Farkhad, et al.
Publicado: (2016)

NICOLAS, DETERRED and KEYNOTE 799: focus on escalation of conventionally fractionated chemoradiotherapy by immune checkpoint inhibition in unresectable stage III non-small cell lung cancer
por: Manapov, Farkhad, et al.
Publicado: (2022)

MR-guided radiotherapy in node-positive non-small cell lung cancer and severely limited pulmonary reserve: a report proposing a new clinical pathway for the management of high-risk patients
por: Eze, Chukwuka, et al.
Publicado: (2022)

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
por: Gray, Jhanelle E., et al.
Publicado: (2019)

Positron Emission Tomography/Computed Tomography (PET/CT)-Based, Local Consolidative Radiotherapy after Chemoimmunotherapy in Metastatic, Non-Oncogene-Addicted Non-Small-Cell Lung Cancer (NSCLC)
por: Angelini, Lucia, et al.
Publicado: (2023)

Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP
por: Faehling, Martin, et al.
Publicado: (2020)

Moderate hypofractionated image-guided thoracic radiotherapy for locally advanced node-positive non-small cell lung cancer patients with very limited lung function: a case report
por: Manapov, Farkhad, et al.
Publicado: (2017)

Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC
por: Jing, Wang, et al.
Publicado: (2022)

Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC
por: Kuge, Tomoki, et al.
Publicado: (2023)

Dose-volumetric parameters and prediction of severe acute esophagitis in patients with locally-advanced non small-cell lung cancer treated with neoadjuvant concurrent hyperfractionated-accelerated chemoradiotherapy
por: Manapov, Farkhad, et al.
Publicado: (2013)

Novel Multimodal Management of Post-Partum Synchronous Metastatic Pulmonary EBV-Associated Lymphoepithelioma-Like Carcinoma (LELC)—A Case Report
por: Pazos, Montserrat, et al.
Publicado: (2021)

Concurrent Afatinib and Whole-Brain Radiotherapy in Exon 19-del-EGFR Mutant Lung Adenocarcinoma: A Case Report and Mini Review of the Literature
por: Eze, Chukwuka, et al.
Publicado: (2017)

Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience
por: Noronha, Vanita, et al.
Publicado: (2020)

IMRT in the treatment of locally advanced or inoperable NSCLC in the pre-durvalumab era: clinical outcomes and pattern of relapses, experience from the Oscar Lambret Center
por: Le Roy, Thomas, et al.
Publicado: (2023)

Revisiting the role of dose escalation in esophageal cancer in the era of modern radiation delivery
por: Eze, Chukwuka, et al.
Publicado: (2020)

Durvalumab in NSCLC: latest evidence and clinical potential
por: Muñoz-Unceta, Nerea, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8c3iskhhqttev4rddl31pl26v0